VIVS Fundamental Analysis - VIVOSIM LABS INC

Fundamental Rating

Taking everything into account, VIVS scores 4 out of 10 in our fundamental rating. VIVS was compared to 533 industry peers in the Biotechnology industry. While VIVS has a great health rating, there are worries on its profitability. VIVS has a correct valuation and a medium growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

VIVS had positive earnings in the past year.

In the past year VIVS has reported a negative cash flow from operations.

In the past 5 years VIVS always reported negative net income.

VIVS had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

The Return On Assets of VIVS (-16.59%) is better than 79.36% of its industry peers.

Looking at the Return On Equity, with a value of -20.83%, VIVS belongs to the top of the industry, outperforming 83.68% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-16.59%
ROE	-20.83%
ROIC	N/A

ROA(3y)-111.01%

ROA(5y)-81.92%

ROE(3y)-181.24%

ROE(5y)-124.91%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 97.89%, VIVS belongs to the top of the industry, outperforming 97.37% of the companies in the same industry.

VIVS's Gross Margin has improved in the last couple of years.

VIVS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	97.89%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5Y2.58%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

VIVS does not have a ROIC to compare to the WACC, probably because it is not profitable.

VIVS has less shares outstanding than it did 1 year ago.

Compared to 5 years ago, VIVS has less shares outstanding

There is no outstanding debt for VIVS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -41.50, we must say that VIVS is in the distress zone and has some risk of bankruptcy.

The Altman-Z score of VIVS (-41.50) is worse than 91.93% of its industry peers.

VIVS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-41.5

ROIC/WACCN/A

WACC8.64%

2.3 Liquidity

A Current Ratio of 4.52 indicates that VIVS has no problem at all paying its short term obligations.

VIVS has a Current ratio (4.52) which is in line with its industry peers.

VIVS has a Quick Ratio of 4.52. This indicates that VIVS is financially healthy and has no problem in meeting its short term obligations.

VIVS has a Quick ratio of 4.52. This is comparable to the rest of the industry: VIVS outperforms 53.66% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	4.52
Quick Ratio	4.52

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 297.92% over the past year.

The Revenue has grown by 94.52% in the past year. This is a very strong growth!

The Revenue for VIVS have been decreasing by -42.03% on average. This is quite bad

EPS 1Y (TTM)297.92%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-397.81%

Revenue 1Y (TTM)94.52%

Revenue growth 3Y-54.21%

Revenue growth 5Y-42.03%

Sales Q2Q%-5.13%

3.2 Future

VIVS is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -6.30% yearly.

The Revenue is expected to grow by 16.82% on average over the next years. This is quite good.

EPS Next Y2.6%

EPS Next 2Y-6.3%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year18.24%

Revenue Next 2Y16.82%

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 0.80, the valuation of VIVS can be described as very cheap.

99.81% of the companies in the same industry are more expensive than VIVS, based on the Price/Earnings ratio.

VIVS is valuated cheaply when we compare the Price/Earnings ratio to 26.15, which is the current average of the S&P500 Index.

The Forward Price/Earnings Ratio is negative for VIVS. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	0.8
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

VIVS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

VIVS's earnings are expected to decrease with -6.30% in the coming years. This may justify a cheaper valuation.

PEG (NY)0.31

PEG (5Y)N/A

EPS Next 2Y-6.3%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

VIVS does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

VIVOSIM LABS INC

NASDAQ:VIVS (11/26/2025, 8:08:00 PM)

2.19

0 (0%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)02-19 2025-02-19/bmo

Earnings (Next)N/A N/A

Inst Owners5.07%

Inst Owner ChangeN/A

Ins Owners0.6%

Ins Owner ChangeN/A

Market Cap5.69M

Revenue(TTM)142.00K

Net Income(TTM)-1.99M

Analysts45.71

Price TargetN/A

Short Float %19.31%

Short Ratio0.77

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)1

Avg Revenue beat(2)-7.06%

Min Revenue beat(2)-22.82%

Max Revenue beat(2)8.7%

Revenue beat(4)1

Avg Revenue beat(4)-22.23%

Min Revenue beat(4)-46.52%

Max Revenue beat(4)8.7%

Revenue beat(8)2

Avg Revenue beat(8)-39.63%

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)0%

EPS NQ rev (3m)0%

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)0%

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	0.8
Fwd PE	N/A
P/S	40.1
P/FCF	N/A
P/OCF	N/A
P/B	0.6
P/tB	0.6
EV/EBITDA	N/A

EPS(TTM)2.75

EY125.57%

EPS(NY)-0.89

Fwd EYN/A

FCF(TTM)-4.01

FCFYN/A

OCF(TTM)-4.01

OCFYN/A

SpS0.05

BVpS3.67

TBVpS3.67

PEG (NY)0.31

PEG (5Y)N/A

Graham Number15.07

Profitability

		Industry Rank	Sector Rank
ROA	-16.59%
ROE	-20.83%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	97.89%
FCFM	N/A

ROA(3y)-111.01%

ROA(5y)-81.92%

ROE(3y)-181.24%

ROE(5y)-124.91%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5Y2.58%

F-Score5

Asset Turnover0.01

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	4.52
Quick Ratio	4.52
Altman-Z	-41.5

F-Score5

WACC8.64%

ROIC/WACCN/A

Cap/Depr(3y)52.61%

Cap/Depr(5y)295.14%

Cap/Sales(3y)51.89%

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)297.92%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-397.81%

EPS Next Y2.6%

EPS Next 2Y-6.3%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)94.52%

Revenue growth 3Y-54.21%

Revenue growth 5Y-42.03%

Sales Q2Q%-5.13%

Revenue Next Year18.24%

Revenue Next 2Y16.82%

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y14.96%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y33.39%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y31.95%

OCF growth 3YN/A

OCF growth 5YN/A

VIVOSIM LABS INC / VIVS FAQ

What is the ChartMill fundamental rating of VIVOSIM LABS INC (VIVS) stock?

ChartMill assigns a fundamental rating of 4 / 10 to VIVS.

What is the valuation status for VIVS stock?

ChartMill assigns a valuation rating of 4 / 10 to VIVOSIM LABS INC (VIVS). This can be considered as Fairly Valued.

What is the profitability of VIVS stock?

VIVOSIM LABS INC (VIVS) has a profitability rating of 3 / 10.

Can you provide the financial health for VIVS stock?

The financial health rating of VIVOSIM LABS INC (VIVS) is 7 / 10.

VIVOSIM LABS INC (VIVS) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

VIVOSIM LABS INC / VIVS FAQ

What is the ChartMill fundamental rating of VIVOSIM LABS INC (VIVS) stock?

What is the valuation status for VIVS stock?

What is the profitability of VIVS stock?

Can you provide the financial health for VIVS stock?